<?xml version="1.0" encoding="UTF-8"?>
<p id="Par40">Chen et al. [
 <xref ref-type="bibr" rid="CR18">18</xref>] have used oseltamivir (75 mg), lopinavir (500 mg), ritonavir (500 mg) per os twice daily followed by ganciclovir (0.25 g) intravenously for 3â€“14 days in COVID-19 infected patients and they have shown safety hence can be considered as treatment options [
 <xref ref-type="bibr" rid="CR18">18</xref>]. EIDD-2801 compound has proven effective against influenza viruses and can be evaluated against SARS-CoV-2 as well [
 <xref ref-type="bibr" rid="CR178">178</xref>].
</p>
